---
title: "罗氏：直接面向患者的项目聚焦美国部分市场的当日送达服务，提高未充分投保、未投保或自费患者的支付能力。"
description: "罗氏：直接面向患者的项目聚焦美国部分市场的当日送达服务，提高未充分投保、未投保或自费患者的支付能力。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/261480597.md"
published_at: "2025-10-16T15:47:10.000Z"
---

# 罗氏：直接面向患者的项目聚焦美国部分市场的当日送达服务，提高未充分投保、未投保或自费患者的支付能力。

罗氏：直接面向患者的项目聚焦美国部分市场的当日送达服务，提高未充分投保、未投保或自费患者的支付能力。

### Related Stocks

- [RHHBY.US - 罗氏(ADR)](https://longbridge.com/zh-CN/quote/RHHBY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Fitch Maintains Ratings of Hikma, Roche Following Corporate Rating Criteria Updates | Fitch Maintains Ratings of Hikma, Roche Following Corporate Rating Criteria Updates | [Link](https://longbridge.com/zh-CN/news/275874477.md) |
| Roche Appoints Mark Dawson As New Head Of Roche Pharma Research And Early Development | Roche Holding AG :ROCHE HOLDING AG - APPOINTMENT OF MARK DAWSON, M.D., PH.D., AS NEW HEAD OF ROCHE PHARMA RESEARCH AND E | [Link](https://longbridge.com/zh-CN/news/276097246.md) |
| Roche's Gazyva Meets Main Goal in Late-stage Kidney Disease Study | Roche's Gazyva Meets Main Goal in Late-stage Kidney Disease Study | [Link](https://longbridge.com/zh-CN/news/276037536.md) |
| Genentech Reports Positive Phase III Results For Gazyva In Primary Membranous Nephropathy | Genentech, part of the Roche Group, announced positive Phase III results for Gazyva in treating primary membranous nephr | [Link](https://longbridge.com/zh-CN/news/276037337.md) |
| Roche Says Its Blood Cancer Drug Shows Positive Results in Trial | Roche announced that its blood cancer drug Gazyva/Gazyvaro has shown positive results in a late-stage trial for patients | [Link](https://longbridge.com/zh-CN/news/276037735.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。